Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD (NXT-DKD)
Evidence-Based Evaluation of Naoxintong Capsule in the Treatment of Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality. Despite current standard therapies including renin-angiotensin system inhibitors (ACEI/ARB), glycemic control, and blood pressure management, disease progression remains inadequately controlled in many patients.
Naoxintong Capsule is a traditional Chinese medicine formulation composed of 16 herbal ingredients (Astragalus membranaceus, Prunus persica seed, Carthamus tinctorius, Paeonia lactiflora, Angelica sinensis, Ligusticum chuanxiong, Boswellia carterii, Commiphora myrrha, Salvia miltiorrhiza, Achyranthes bidentata, Cinnamomum cassia, Morus alba, Spatholobus suberectus, Buthus martensii, Pheretima aspergillum, and Hirudo nipponica). It has been widely used in China for cardiovascular and cerebrovascular diseases, with demonstrated effects on endothelial protection, anti-inflammation, anti-thrombosis, and plaque stabilization.
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Naoxintong Capsule added to standard conventional therapy in slowing the progression of diabetic nephropathy and providing cardiovascular protection. A total of 410 patients with Type 2 diabetic nephropathy will be randomized (1:1) to receive either Naoxintong Capsules (4 capsules, 3 times daily) or matching placebo, in addition to standard therapy, for 12 months. The primary outcome is the annual rate of decline in estimated glomerular filtration rate (eGFR). Secondary outcomes include changes in proteinuria, CKD stage progression, time to end-stage kidney disease, major adverse cardiovascular events, TCM syndrome scores, and quality of life measures.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
BACKGROUND AND RATIONALE
Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in economically developed countries. China has the largest diabetic population globally, and DN now accounts for approximately 30% of new dialysis patients. Despite the beneficial effects of ACE inhibitors (ACEI) and Angiotensin II receptor blockers (ARB) in the microalbuminuric stage, landmark trials (RENNAL, IDNT, VA NEPHRON-D) have shown that these agents alone or in combination fail to significantly reduce cardiovascular events and all-cause mortality in advanced DN. There is an urgent need for novel therapeutic approaches to slow DN progression and improve survival.
Naoxintong Capsule (National Drug Approval No.: Guoyaozhunzi Z20025001) is a well-established traditional Chinese medicine formulation that has been widely used in China for cardiovascular and cerebrovascular diseases. It comprises 16 herbal and animal-derived ingredients that collectively exert effects through endothelial protection, anti-inflammatory activity, inhibition of thrombosis, and plaque stabilization. Based on the integrative medicine concept of brain-heart-kidney co-treatment and the shared pathophysiological mechanisms underlying DN progression and cardiovascular complications, Naoxintong Capsule represents a promising adjunctive therapy for DN.
STUDY DESIGN AND OBJECTIVES
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to provide high-level evidence for the efficacy and safety of Naoxintong Capsule in treating DN. The study will enroll 410 adult patients with confirmed Type 2 diabetic nephropathy across approximately 20 clinical centers in China.
The primary objective is to evaluate whether adding Naoxintong Capsule to standard conventional therapy can slow the annual rate of eGFR decline compared with standard therapy alone (with placebo). Secondary objectives include assessing effects on proteinuria, CKD stage progression, time to ESKD, cardiovascular events, traditional Chinese medicine (TCM) syndrome scores, and health-related quality of life.
PARTICIPANT POPULATION
Eligible participants are adults (age >= 18 years) with confirmed Type 2 diabetic nephropathy, 24-hour urinary protein excretion between 0.5 and 3.5 g, eGFR >= 45 mL/min/1.73m2, and on stable ACEI/ARB therapy for at least 8 weeks prior to enrollment. Patients must discontinue all other traditional Chinese medicine products for a washout period of at least 4 weeks before randomization.
INTERVENTION
Participants will be randomized (1:1) to receive either Naoxintong Capsules or matching placebo capsules, both administered as 4 capsules per dose, 3 times daily, taken orally 30 to 60 minutes after meals. All participants continue to receive standard conventional therapy for DN, including glycemic control, blood pressure management, lipid-lowering therapy, dietary management, and treatment of CKD-related complications as clinically indicated. The treatment duration is 12 months.
FOLLOW-UP AND ASSESSMENTS
Following randomization at Visit 1 (V1), participants will attend scheduled visits at Month 1 (V2), Month 3 (V3), Month 6 (V4), Month 9 (V5), and Month 12 (V6). At each visit, clinical assessments include physical examination, laboratory tests (urinalysis, 24-hour urine protein, urine albumin-to-creatinine ratio, complete blood count, blood biochemistry including renal function, HbA1c, lipid profile, hs-CRP, IL-6), ECG, TCM syndrome scoring, and adverse event monitoring. At selected visits (V1, V6), additional imaging studies (chest X-ray/CT, renal ultrasound) and optional fundoscopy are performed. Biological samples (blood, urine, stool) are collected at V1, V4, and V6 for exploratory analyses including gut microbiota and metabolomics.
SAMPLE SIZE
The sample size of 410 (205 per group) was calculated based on detecting a clinically meaningful difference of 1.0 mL/min/1.73m2/year in eGFR annual decline slope between groups (expected: -3.0 vs. -2.0 mL/min/1.73m2/year), with a pooled standard deviation of 3.2, at a two-sided alpha of 0.05 and 80% power, allowing for a 20% dropout rate.
STATISTICAL ANALYSIS
Efficacy analyses will be conducted on both the Full Analysis Set (FAS, intention-to-treat) and the Per-Protocol Set (PPS). The primary analysis will use a mixed-effects model for the eGFR slope, adjusting for center effect. Time-to-event outcomes will be analyzed using Kaplan-Meier methods and Cox proportional hazards models. Safety analyses will be performed on the FAS.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- China-Japan Friendship Hospital
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
Beijing, Beijing Municipality, China, 100853
- Chinese PLA General Hospital, First Medical Center
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China
- Daping Hospital, Army Medical University
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
-
Liaoning
-
Dalian, Liaoning, China
- First Affiliated Hospital of Dalian Medical University
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
Shanghai, Shanghai Municipality, China
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
Shanghai, Shanghai Municipality, China
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Provincial Hospital of Traditional Chinese Medicine
-
Contato:
- Zheyi Dong, MD
- Número de telefone: 010-66937763
- E-mail: shengdai26@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age >= 18 years.
Meets the diagnostic criteria for Type 2 diabetic nephropathy, defined as:
- Confirmed diagnosis of Type 2 diabetes mellitus; AND
- At least one of the following: urinary albumin-to-creatinine ratio (UACR) >= 30 mg/g, or eGFR < 60 mL/min/1.73m^2, confirmed by repeat testing (interval >= 3 months), after excluding transient factors such as acute kidney injury, dehydration, infection, or heart failure; OR
- Renal biopsy confirmed as isolated diabetic nephropathy; AND
- Exclusion of other primary or secondary kidney diseases.
- 24-hour urinary protein excretion >= 0.5 g and < 3.5 g.
- Estimated glomerular filtration rate (eGFR) >= 45 mL/min/1.73m^2.
- On a stable dose of ACE inhibitor (ACEI) or Angiotensin II receptor blocker (ARB) therapy for at least 8 weeks prior to enrollment. If SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), or GLP-1 receptor agonists are being used, the dose must have been stable for at least 4 weeks prior to enrollment and remain unchanged during the study period. Patients not currently using these agents must not initiate them during the study.
- Signed informed consent form.
Exclusion Criteria:
- Type 1 diabetes mellitus or other types of diabetes mellitus (e.g., secondary diabetes, maturity-onset diabetes of the young).
- Coexisting systemic autoimmune or immune-mediated disease where the clinical assessment suggests a non-diabetic nephropathy etiology.
- Decline in eGFR of > 30% within the past 3 months.
- Persistent serum potassium > 5.5 mmol/L.
- Diagnosis of hemorrhagic cardiovascular or cerebrovascular disease within the past 3 months.
- Known allergy or hypersensitivity to any component of Naoxintong Capsule or placebo; pregnant or lactating women.
- Participation in another drug or medical device clinical trial within the past 6 months.
- Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in the clinical trial (e.g., severe hepatic dysfunction, life expectancy < 1 year).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Naoxintong Capsule Group
Participants will receive Naoxintong Capsules (4 capsules per dose, 3 times daily, orally, 30-60 minutes after meals) in addition to standard conventional therapy for diabetic nephropathy, for a total treatment duration of 12 months.
Standard conventional therapy includes glycemic control (oral hypoglycemic agents and/or insulin), blood pressure management (ACEI or ARB, with optional non-RASI antihypertensives), lipid-lowering therapy (statins as indicated), dietary management (protein 0.6-0.8
g/kg/day, sodium <3 g/day), and treatment of CKD-related complications as clinically indicated.
|
Naoxintong Capsule is a traditional Chinese medicine formulation composed of 16 herbal and animal-derived ingredients: Astragalus membranaceus (Huangqi), Prunus persica seed (Taoren), Carthamus tinctorius flower (Honghua), Paeonia lactiflora root (Chishao), Angelica sinensis root (Danggui), Ligusticum chuanxiong rhizome (Chuanxiong), Boswellia carterii resin (Ruxiang), Commiphora myrrha resin (Moyao), Salvia miltiorrhiza root (Danshen), Achyranthes bidentata root (Niuxi), Cinnamomum cassia twig (Guizhi), Morus alba twig (Sangzhi), Spatholobus suberectus stem (Jixueteng), Buthus martensii (Quanxie), Pheretima aspergillum (Dilong), and Hirudo nipponica (Shuizhi).
Each capsule contains 0.4 g of active ingredients.
Dosage: 4 capsules (1.6 g) per dose, taken orally 3 times daily, 30-60 minutes after meals.
Manufactured by Shaanxi Buchang Pharmaceutical Co., Ltd.
(National Drug Approval No.: Guoyaozhunzi Z20025001).
Storage: sealed, at room temperature.
Shelf life: 24 months.
|
|
Comparador de Placebo: Placebo Group
Participants will receive matching placebo capsules (4 capsules per dose, 3 times daily, orally, 30-60 minutes after meals) in addition to standard conventional therapy for diabetic nephropathy, for a total treatment duration of 12 months.
Standard conventional therapy is identical to that provided in the Naoxintong group.
|
Matching placebo capsules identical in appearance, size, shape, color, weight, packaging, and labeling to Naoxintong Capsules but containing no active pharmaceutical or herbal ingredients.
Dosage: 4 capsules per dose, taken orally 3 times daily, 30-60 minutes after meals.
Manufactured by Shaanxi Buchang Pharmaceutical Co., Ltd.
Storage: sealed, at room temperature.
Shelf life: 24 months.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Annual Rate of Decline in Estimated Glomerular Filtration Rate (eGFR)
Prazo: Baseline to Month 12
|
The annual rate of decline in eGFR (ml/min/1.73m^2/year),
calculated as the slope of eGFR over the 12-month treatment period using all available eGFR measurements at each scheduled visit.
eGFR is estimated using the CKD-EPI equation.
A less negative slope indicates slower disease progression.
|
Baseline to Month 12
|
|
Change in 24-Hour Urinary Protein Excretion From Baseline
Prazo: Baseline to Month 12
|
Change from baseline in 24-hour urinary protein excretion (g/24h), measured at each scheduled visit.
A decrease indicates renal protective effect.
|
Baseline to Month 12
|
|
Renal Composite Endpoint: eGFR Decline >30%, ESKD, or MACE
Prazo: From randomization through Month 12
|
Time to first occurrence of: sustained eGFR decline >30% from baseline; end-stage kidney disease; or major adverse cardiovascular event.
|
From randomization through Month 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants With CKD Stage Improvement, Stabilization, or Progression
Prazo: Baseline to Month 12
|
Proportion of participants whose CKD stage (KDIGO eGFR categories) improved, remained stable, or progressed.
|
Baseline to Month 12
|
|
Time to Sustained eGFR Decline of Greater Than 30% From Baseline
Prazo: From randomization through Month 12
|
Time from randomization to first confirmed sustained eGFR decline exceeding 30% from baseline.
|
From randomization through Month 12
|
|
Time to End-Stage Kidney Disease (ESKD)
Prazo: From randomization through Month 12
|
Time from randomization to ESKD: maintenance dialysis, kidney transplantation, or sustained eGFR <15.
|
From randomization through Month 12
|
|
Time to First Unplanned Hospitalization for Heart Failure
Prazo: From randomization through Month 12
|
Time from randomization to first unplanned hospital admission primarily due to heart failure.
|
From randomization through Month 12
|
|
Time to First Non-Fatal Myocardial Infarction
Prazo: From randomization through Month 12
|
Time from randomization to first non-fatal MI per WHO-MONICA criteria.
|
From randomization through Month 12
|
|
Time to First Non-Fatal Ischemic Stroke
Prazo: From randomization through Month 12
|
Time from randomization to first non-fatal ischemic stroke with imaging confirmation.
|
From randomization through Month 12
|
|
Time to Cardiovascular Death or Stroke-Related Death
Prazo: From randomization through Month 12
|
Time from randomization to death attributable to cardiovascular or cerebrovascular causes.
|
From randomization through Month 12
|
|
Time to All-Cause Death
Prazo: From randomization through Month 12
|
Time from randomization to death from any cause.
|
From randomization through Month 12
|
|
Change in TCM Syndrome Score From Baseline
Prazo: Baseline to Month 12
|
Change in TCM syndrome score using a standardized 90-item questionnaire.
|
Baseline to Month 12
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NXT-DKD-2026-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .